Forteo/Forsteo (teriparatide) is licensed for postmenopausal, male and glucocorticoid-induced osteoporosis at high fracture risk, capped at a single 24-month lifetime course, and EMA-approved biosimilars and US generic teriparatide now sit alongside the originator pen.
M Care Exports supplies Forteo/Forsteo (teriparatide), Eli Lilly's recombinant human parathyroid hormone fragment PTH(1-34), an anabolic bone-formation agent rather than an antiresorptive. It is dosed as a daily 20 mcg subcutaneous injection from a prefilled pen, cold-chain throughout, for a lifetime maximum of 24 months. M Care is a merchant exporter: we source the originator pen and EMA-authorised biosimilars or FDA-approved generic teriparatide through licensed Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Teriparatide exporter and bulk supplier from India.
For hospital pharmacy, homecare-service and MoH tender-desk orders, M Care quotes teriparatide against buyer specification: originator (Forteo/Forsteo) or biosimilar/generic pen, destination-market regulatory documentation and validated cold-chain routing from licensed WHO-GMP manufacturer lines on the M Care roster. Because teriparatide must stay at 2 degC to 8 degC from dispatch through the patient's 28-day in-use window and its licensed course cannot exceed 24 months per patient, we confirm the buyer's cold-chain capability and intended treatment-duration tracking before dispatch, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Parathyroid hormone analogue, anabolic bone-formation agent, sourced and documented for export.
Teriparatide is the biologically active 1-34 amino-acid fragment of human parathyroid hormone, an anabolic agent that stimulates new bone formation, unlike bisphosphonates and other antiresorptives that only slow bone loss. It is given by daily subcutaneous injection, not orally, and needs no reconstitution: the pen is ready to use directly from the fridge. The FDA label's flagship indications are osteoporosis in postmenopausal women at high fracture risk and, separately, increasing bone mass in men with primary or hypogonadal osteoporosis at high fracture risk; the EU SmPC and FDA label both add glucocorticoid-induced osteoporosis in men and women on long-term systemic steroids at high fracture risk. A lifetime treatment course is capped at 24 months and cannot be repeated, a restriction not shared by antiresorptive comparators on a tender shortlist. Forteo/Forsteo is supplied as a 250 mcg/mL solution in a single-patient prefilled pen delivering 28 daily doses of 20 mcg.
Active ingredient
Teriparatide (recombinant human parathyroid hormone 1-34). Parathyroid hormone analogue, anabolic bone-formation agent.
Forms and strengths
20 mcg per dose, pre-filled pen (250 mcg/mL).
Indications
Teriparatide is the biologically active 1-34 amino-acid fragment of recombinant human parathyroid hormone, an anabolic agent that stimulates new bone formation and is licensed for osteoporosis at high fracture risk in postmenopausal women, men, and glucocorticoid-induced osteoporosis. Supplied from Indian WHO-GMP-sourced channels as originator, biosimilar or generic pens to regulated and semi-regulated markets, cold-chain throughout.
Administration
Subcutaneous. Solution for injection in a prefilled pen.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for teriparatide are mainly hospital and specialist secondary-care pharmacies managing postmenopausal, male and glucocorticoid-induced osteoporosis patients at high fracture risk, alongside homecare-delivery services, licensed importers and MoH tender desks. In the UK, teriparatide is prescribed under NICE-aligned secondary-care pathways and dispensed through homecare services rather than retail pharmacy, so buyers are typically NHS trust pharmacy or homecare-provider procurement teams, not community chemists. In GCC and African markets, buyers are hospital and MoH tender desks sourcing cold-chain-validated originator or biosimilar/generic pens for specialist endocrinology and rheumatology clinics. India is our origin. We do not sell into the Indian market. Teriparatide is exported only, and every quote is routed through a licensed importer or distributor in the destination country.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on teriparatide.
Confirm the patient's cumulative lifetime teriparatide exposure before dispensing: courses are capped at 24 months in total and are not repeatable, so a homecare or hospital pharmacy restarting a patient after a treatment gap must check prior exposure, not just the current prescription date. The pen must stay at 2 degC to 8 degC from the moment it leaves cold storage; once a patient starts using it, it is good for a maximum of 28 days at that same fridge temperature, and any pen that has been frozen must be discarded, not warmed and reused. Screen for contraindications before the first dose: pre-existing hypercalcaemia, severe renal impairment, prior skeletal irradiation, bone metastases or skeletal malignancy, Paget's disease and unexplained elevated alkaline phosphatase all rule teriparatide out. Because it is self-administered daily by the patient or a carer, injection-technique training at initiation and a homecare-delivery plan matter as much as the drug itself; a missed cold-chain link in transit is the most common preventable failure point we see flagged back to the exporter.
The documentation pack a regulator actually asks for.
Teriparatide is a recombinant peptide biologic, not a small-molecule generic, so buyers should treat brand and biosimilar or generic choice as genuinely interchangeable rather than assume automatic substitution: EMA-authorised biosimilars Terrosa (Gedeon Richter, EU marketing authorisation January 2017) and Movymia (STADA Arzneimittel, EU marketing authorisation January 2017) sit alongside the originator following patent expiry, and FDA-approved generic teriparatide injection followed in the US from late 2023. Teriparatide does not appear on the WHO Model List of Essential Medicines. It is not a controlled substance. M Care does not hold WHO-GMP or WHO-PQ status itself; we source WHO-GMP-sourced teriparatide, biosimilar and generic lines through licensed Indian manufacturing and distribution channels and quote against the buyer's specified regulatory pathway.
The paperwork above is the molecule-specific part; the general pathway a destination regulator expects is set out in our licensed import route guide.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside teriparatide.
Aceclofenac
Another musculoskeletal & pain line ordered on the same formularies.
Allopurinol
Another musculoskeletal & pain line ordered on the same formularies.
Celecoxib
Another musculoskeletal & pain line ordered on the same formularies.
All musculoskeletal & pain
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for teriparatide.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Teriparatide supply, the specific questions.
We're looking for a teriparatide supplier who can guarantee cold chain all the way to our tender destination. Can M Care do that?
Yes. Teriparatide must stay at 2 degC to 8 degC from dispatch through the patient's 28-day in-use window, so we route every quote through validated cold-chain lanes and confirm the buyer's own cold-chain capability at the receiving end before dispatch. We do not ship teriparatide outside temperature-controlled logistics.
Is there a generic or biosimilar alternative to Forteo/Forsteo we should be quoting instead of the originator brand?
Yes, and it is a legitimate choice, not a compromise. EMA-authorised biosimilars Terrosa and Movymia have held EU marketing authorisation since 2017, and FDA-approved generic teriparatide injection has been available in the US since late 2023. M Care quotes originator Forteo/Forsteo or biosimilar/generic teriparatide against your specification, so the choice comes down to your budget and destination-market registration status, not clinical compromise.
We need a partner for osteoporosis therapy that isn't the usual bisphosphonate. What's distinctive about teriparatide?
Teriparatide is an anabolic agent: it stimulates new bone formation, whereas bisphosphonates and most other osteoporosis therapies only slow bone loss. It is licensed for postmenopausal women, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis, all at high fracture risk, per the FDA label and EU SmPC. It is given as a daily self-administered subcutaneous injection from a prefilled pen, not as a tablet.
How long can a patient stay on teriparatide, and does that affect how we should be forecasting tender volumes?
Teriparatide carries a lifetime treatment cap of 24 months per patient, and the course is not repeatable. For tender and formulary forecasting, that means demand is driven by new patient starts against that fixed course length, not by indefinite repeat prescribing, which is a different volume pattern from most chronic osteoporosis therapies on a shortlist.
Is teriparatide the kind of drug our hospital tender desk buys, or is it a primary-care item?
It is secondary-care and specialist-initiated. In the UK, teriparatide is prescribed under NICE-aligned pathways for secondary prevention of osteoporotic fragility fractures and dispensed through homecare-delivery services rather than community pharmacy. MoH tender desks in the GCC and Africa likewise route teriparatide through hospital and specialist endocrinology or rheumatology clinics rather than retail channels.
What should we check before a teriparatide shipment leaves India?
We confirm the buyer's licensed-importer or distributor status, the destination regulator's dossier requirements (CTD/eCTD or country-specific), validated cold-chain routing at 2 degC to 8 degC, and whether the buyer wants originator Forteo/Forsteo or an EMA/FDA-approved biosimilar or generic. Teriparatide is a WHO-GMP-sourced biologic, not something M Care manufactures itself; we source and quote against your specification.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-25.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.